Q-omics provides the consensus-scored JPH3 profile across patient tissues and cancer cell-line models. JPH3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, JPH3 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, JPH3 RNA expression shows 16,158 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where JPH3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for JPH3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes JPH3 survival associations across molecular data types. JPH3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible JPH3 RNA expression–survival associations across cancer types. High JPH3 expression shows unfavorable associations in ACC, KIRP, MESO and COAD, but favorable associations in LGG and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for JPH3 RNA expression.
This table summarizes JPH3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for JPH3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. JPH3 shows lower tumor expression in COAD and UCEC and higher tumor expression in HNSC, LUAD, BRCA and LUSC. The COAD box plot shows higher JPH3 RNA expression in normal versus tumor tissue (log2 FC = −0.475, t-test p < 0.001).
This table shows molecular features associated with JPH3 in patient tissues and cancer cell lines. In patient samples, JPH3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, JPH3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
